BRACCO
SpecialtyBRACCO is a specialty pharmaceutical company focused on Oncology, Cardiovascular, Respiratory. Key products include LUMASON.
BRACCO at a Glance
- Fast trial execution (24 months median completion)
BRACCO's Key Drugs
BRACCO's core commercial portfolio centers on VARIBAR PUDDING, LUMASON, E-Z-DISK, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Oral and pharyngeal function impairment
Focal Liver Lesions
Esophageal Patency
Fecal tagging during CT colonography
Visualization of the gastrointestinal tract during small bowel radiographic examinations
BRACCO's Recent FDA Approvals
BRACCO secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
BRACCO's Therapeutic Areas
BRACCO's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 28 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BRACCO's Top Competitors
BRACCO's closest competitors by therapeutic-area and drug-target overlap include Merck, AstraZeneca, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BRACCO Pipeline Snapshot
BRACCO has 14 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 5 Phase 2 and 4 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VARIBAR PUDDING leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/8 completed
- • Speed: 24 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (14)
Discontinued (2)
Company Info
- First Approval
- 1954-04-27
- Latest
- 2026-05-13
- Applications
- 44
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges